Healthcare / BiotechnologyHKSE
$17.30
-0.81 (-4.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-429.3M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.5%
↓Gross Margin
63.6%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-193.4%
FCF / Net income
2.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $125.7M · net income $-97.9M · FCF $-243.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $125.7M | $125.7M | $39.4M | — | — |
| Net Income | $-97.9M | $-97.9M | $-798.1M | $-747.8M | $-892.2M |
| EBITDA | $-66.5M | $-66.5M | $-712.5M | $-655.3M | $-793.9M |
| EPS | -0.18 | -0.18 | -1.44 | -1.34 | -1.62 |
| Gross Margin | 63.6% | 63.6% | 37.4% | — | — |
| Operating Margin | -181.7% | -181.7% | -1455.2% | — | — |
| Net Margin | -77.9% | -77.9% | -2024.4% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.16 | 0.05 | 0.05 |
| Current Ratio | 5.73 | 5.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-243.0M | $-243.0M | $-429.3M | $-464.5M | $-781.7M |
| Returns | |||||
| ROE | -12.5% | -12.5% | -75.5% | -41.5% | -36.1% |
| Valuation | |||||
| P/B | 12.19 | 12.19 | 5.04 | 1.86 | 3.54 |
| Growth & Yield | |||||
| Revenue Growth | 218.7% | 218.7% | — | — | — |
| EPS Growth | 87.5% | 87.5% | -7.5% | 17.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.44 → -0.18
Residual
-15.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.